Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07241234RecruitingPhase 1
Study of an experimental drug for phenylketonuria (PKU)
This trial tests an investigational drug (AG-181) for people with PKU who have a specific genetic change (R408W mutation). It aims to check if the drug is safe and how it works in your body.
Indianapolis, IndianaAges 18–69 - NCT07249463RecruitingPhase 2
Testing a new drug for cryptosporidium infection in healthy adults
This trial tests a new drug, EDI048, to see how well it works and how safe it is for treating cryptosporidium infection. It is for healthy volunteers who will be intentionally exposed to the infection under controlled conditions.
Baltimore, MarylandAges 18–50 - NCT07241923RecruitingPhase 1
SYH2070 injection safety study for high triglycerides and high cholesterol
This study tests a new injection called SYH2070 for people with high triglycerides and high LDL cholesterol. The goal is to see if a single dose is safe and how the body processes the medication. It is for people who have not been on cholesterol-lowering drugs recently.
Shijiazhuang, HebeiAges 18–60 - NCT07243171RecruitingPhase 1/Phase 2
Oral Ecnoglutide for overweight or obesity
This trial tests an oral medication called Ecnoglutide to help people with overweight or obesity lose weight. It is for Chinese adults who are not diabetic and have a stable weight.
Beijing, Beijing MunicipalityAges 18–65 - NCT06900049RecruitingEarly Phase 1
Testing LE051 for boys with Duchenne muscular dystrophy (exon 51)
This study tests a new medicine called LE051 for boys with Duchenne muscular dystrophy (DMD) who have a specific genetic change that allows 'exon 51 skipping.' The goal is to see if it is safe and can help improve muscle function. Boys who join will be closely monitored for heart and lung health.
Shanghai, Shanghai MunicipalityAges 4–8 - NCT07237464RecruitingPhase 1
Safety study of GB18 injection in healthy adults
This early-phase trial tests a new injection called GB18 in healthy adults to see if it is safe and how the body processes it. It may help researchers understand how to treat conditions that involve the immune system.
Beijing, Beijing MunicipalityAges 18–55 - NCT07231120RecruitingPhase 1
Testing SXRN injection for cancer-related weight loss
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Beijing, Beijing MunicipalityAges 18–75 - NCT07230496RecruitingPhase 1
Safety study of an investigational weight-management drug
This study is testing a new investigational drug, either alone or combined with another drug, to see how safe it is and how the body processes it. It is for healthy people who are overweight or obese, and results may help in developing future treatments for weight management.
Sydney, New South WalesAges 18–75 - NCT07235059RecruitingPhase 1
Testing OJR520 in healthy people and those with chronic kidney disease
This study tests a new drug called OJR520 to see if it's safe and how the body processes it. It first tests healthy volunteers and then people with chronic kidney disease to understand the drug's effects.
Miami, FloridaAges 18–65 - NCT07238868RecruitingPhase 2
Long-term safety study of CB03-154 for epilepsy
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
Melbourne, VictoriaAges 18–70 - NCT07235163RecruitingPhase 1
Testing a new medicine in healthy adults
This study tests how a new medicine, PF-08065010, is handled by the body and how safe it is in healthy adults. It helps researchers find the right dose for future studies.
Brussels, Bruxelles-capitale, Région deAges 18–65 - NCT07237659RecruitingPhase 1
Testing safety of NTR-1011 in lupus and rheumatoid arthritis
This trial is testing a new medicine called NTR-1011 to see if it is safe and tolerable for people with lupus or rheumatoid arthritis. If you have active lupus or RA and are on a stable treatment plan, you may be able to join.
Apple Valley, CaliforniaAges 18–75 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT07230652RecruitingPhase 1
Safety study of LY03020 for healthy volunteers and people with schizophrenia
This study tests the safety of a new medication called LY03020. It is for healthy volunteers and for people with stable schizophrenia. The study aims to see how well the body handles the drug and what side effects might occur.
BeijingAges 18–60 - NCT07231705Recruiting
Plant-based formula for growth and tolerance in toddlers
This study tests how well toddlers (12-17 months old) tolerate and grow on a plant-based formula. It compares this new formula to standard ones for children who get most of their calories from formula.
Columbus, OhioAges 1 year–1.4 years - NCT07239856Recruiting
Goat vs. Cow Milk: Which is easier to digest?
This study compares how well people digest goat milk versus cow milk. If you have trouble with cow milk but not goat milk (or can drink both), researchers want to see if goat milk is a better choice for you.
BobignyAges 18–65 - NCT07233434Recruiting
Diabetes screening with sugar drink test in Guadeloupe
This study checks if a special sugar-drink test can find type 2 diabetes in people whose fasting blood sugar is normal but whose HbA1c is slightly high. It is for adults 18–64 of African or Indian descent with certain risk factors.
Pointe-à-Pitre, GuadeloupeAges 18–65 - NCT07223138Enrolling by invitationPhase 3
Long-term safety study of sonelokimab for psoriatic arthritis
This study is for people who have already been in a previous trial of sonelokimab for psoriatic arthritis and want to continue treatment. It checks how safe and effective the medicine is over a longer time.
Avondale, ArizonaAges 18 years+ - NCT07229638RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for solid tumors
This study tests a new drug called SHR-9839 given under the skin, combined with other anti-cancer treatments, for people with solid tumors. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT07228364RecruitingPhase 1
Testing safety of AZD1613 for polycystic kidney disease
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Birmingham, AlabamaAges 18–65 - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Gilbert, ArizonaAges 60 years+ - NCT07217067RecruitingPhase 2
Study of PKN605 for people with atrial fibrillation
This trial tests a new medicine called PKN605 for people with atrial fibrillation (irregular heartbeat). The goal is to see if it can safely help control heart rhythm. You will need to have had at least two AF episodes recently and meet other heart health criteria.
Tupelo, MississippiAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.